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Background: Adjusting for laboratory test results may result in better confounding control when added to
administrative claims data in the study of treatment effects. However, missing values can arise through several
mechanisms.
Methods: We studied the relationship between availability of outpatient lab test results, lab values, and patient and
system characteristics in a large healthcare database using LDL, HDL, and HbA1c in a cohort of initiators of statins or
Vytorin (ezetimibe & simvastatin) as examples.
Results: Among 703,484 patients 68% had at least one lab test performed in the 6 months before treatment.
Performing an LDL test was negatively associated with several patient characteristics, including recent
hospitalization (OR = 0.32, 95% CI: 0.29-0.34), MI (OR = 0.77, 95% CI: 0.69-0.85), or carotid revascularization
(OR = 0.37, 95% CI: 0.25-0.53). Patient demographics, diagnoses, and procedures predicted well who would have
a lab test performed (AUC = 0.89 to 0.93). Among those with test results available claims data explained only
14% of variation.
Conclusions: In a claims database linked with outpatient lab test results, we found that lab tests are performed
selectively corresponding to current treatment guidelines. Poor ability to predict lab values and the high proportion
of missingness reduces the added value of lab tests for effectiveness research in this setting.
Keywords: Insurance claims data, Laboratory test results, Serum lipid levels, Confounding, Imputation,
Pharmacoepidemiology, Lipid lowering therapy, Statin, EzetimibeBackground
Administrative health insurance claims databases pro-
vide comprehensive and longitudinal records of encoun-
ters with the health care system and of drug dispensing,
but lack clinical detail. For example, while the perform-
ance of a lab test will generate a claim, the test result
will not be available within the claims database. This
shortcoming can be overcome by merging outpatient* Correspondence: schneeweiss@post.harvard.edu
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distribution, and reproduction in any mediumlaboratory test results extracted from electronic medical
records (EMR) systems with claims data. Adjusting for
lab results may result in better confounding control
when administrative claims data are used to study treat-
ment effects of medical products.
A difficulty arises from the way in which lab tests are
ordered and performed in the American health care sys-
tem. EMR systems with outpatient lab results generally
rely on major laboratory companies to supply lab results
data; results for patients whose tests are conducted out-
side the large chains may go unrecorded in EMRs. In
conducting comparative effectiveness research in claims
data, pharmacoepidemiologists generally interpret theentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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which can result in a covariate misclassification problem
but not a missing data problem [1]. However, missing lab
test results do not mean the test was not performed or
the results are normal, and thus must be handled like
other missing data. There is little guidance in the litera-
ture on the nature of the missingness of such laboratory
information or whether missing lab test results can be
adequately imputed.
Investigators have employed varying strategies to deal
with this situation. One approach is to identify a sub-
cohort of patients with complete information on the lab
test results of interest. Seeger et al. studied the effective-
ness of statin therapy to reduce myocardial infarction
rates, by requiring all patients studied to have a recorded
LDL > 130 mg/dl [2]. This approach reduces the propor-
tion of subjects with missing data, but that advantage
comes at the cost of fewer subjects in the study, and a
final study population that may be dissimilar to the
broader patient population for important characteristics.
Furthermore, this approach is impractical for multiple
unrelated lab test results, as complete cases may be
few [3].
One unfavorable approach is to include an indicator
term for missing lab test data. In the case of lab results,
missingness can imply three things: (1) the physician didFigure 1 Reasons for missing lab test results in a longitudinal healthc
In the setting of a new user cohort study with a defined covariate assessmnot see a need to have a test ordered; (2) the patient did
not choose to have the test performed, or (3) the test
was performed but not in a facility whose data fed back
to the patient’s EMR (Figure 1). Though the implication
of each of these cases is entirely different, they are indis-
tinguishable in the data; as such, coding them simply as
“missing” would lead to bias. Even if all the missingness
were due to the third case, in which data are most plaus-
ibly missing completely at random, the use of a missing
indicator term could still cause bias [4,5].
In order to further meaningful comparative effectiveness
research, we must understand the selectiveness of missing
lab test results and how missingness may be related to
study outcomes. In this paper, we seek to describe the
analytic issues encountered when lab results may not be
available for many patients. As an example, we describe
the characteristics associated with the absence of labora-
tory test results and the degree to which missingness and
actual lab test values can be predicted based on patient
and health plan characteristics in a population of patients
initiating lipid-lowering therapy.
Methods
Database studies that combine claims and lab test results
or other data from EMRs typically employ the claims as
a “data backbone,” as claims data provide a longitudinalare utilization database linked to a lab test provider database*. *
ent period before the first exposure and before follow-up.
Figure 2 Incident user cohort study*. * The 6-month covariate
assessment period (CAP) precedes the initiation of treatment. During
the CAP we identified patient characteristics, including lab tests
performed and lab test results available. After treatment start
followed a 1-month lag period before events were attributed to the
treatment. The arrows between prescriptions (Rx), diagnoses (Dx)
and lab tests denote the fact that the temporality of events within
the CAP was not considered in this study.
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pensings submitted for health insurance reimbursement.
Increasingly, claims databases link data from large national
lab test chains [6-8]. Though the chains service a large
number of American patients, the resulting linked data
may cover substantially less than 50% of outpatient lab
tests, with coverage highly dependent on the region where
the patient resides and the lab companies servicing that
region. Figure 1 illustrates two levels of missingness that
may arise in such situations. No claim will be recorded
(Level 1) if a physician does not order a test, a patient
receives a lab in a hospital, or a patient does not get a test
that was ordered. The result of a test that was per-
formed may not be transmitted to the patient’s claims
data (Level 2) if the insurer has not established a data
exchange agreement with the laboratory provider. The
likelihood of Level 2 missingness increases if there is no
laboratory provider operating in the area that has a data
exchange agreement with the insurer.
Data sources
We employed longitudinal claims data from 14 Blue
Cross and/or Blue Shield-licensed health plans of
Wellpoint across 14 US states, as represented in the
HealthCore Integrated Research DatabaseSM (HIRDSM).
HealthCore linked claims information to lab test results
provided by two large national laboratory providers, for
laboratory tests performed between January 1, 2005
through June 30, 2010 on patients represented in the
HIRD system. The claims data contained information on
drug dispensings, outpatient medical services, and hospi-
talizations including emergency room visits. All medical
services were coded with up to 9 discharge diagnoses
[1]. Individual laboratory test results were identified by
LOINC codes and standardized across lab providers. This
study was approved by the Brigham and Women’s Hos-
pital Institutional Review Board and signed data use
agreements were in place.
Study cohort and exposure
From the data available, we established a cohort of all
incident users of any statin (simvastatin, pravastatin,
lovastatin, atorvastatin, rosuvastatin), Vytorin (simvastatin
plus ezetimibe), or ezetimibe who were 18 years or older
at the start of treatment. Incident use was established by
requiring at least 12 months of insurance coverage before
treatment and no use of any lipid-lowering therapy
in those 12 months. 1 All covariate information was
assessed in the longitudinal healthcare claims over a
covariate assessment period (CAP) starting 6 months be-
fore treatment initiation and up to the day of dispensing
of the index drug. Follow-up for occurrence of MI
started 1 month after initiation of lipid-lowering treat-
ment, a conservative assumption to allow for the biologicaction of the medication to occur (Figure 2) [9]. We cate-
gorized each medication on the index date into high
and low intensity treatment based on its ability to lower
LDL levels (Table 1) [10].
We defined two subgroups of patients with chronic
conditions. Rheumatoid arthritis (RA) was defined as at
least two outpatient diagnoses of RA in the CAP or one
hospital discharge diagnosis of RA in CAP or one diag-
nosis of RA plus dispensing of a disease modifying anti-
rheumatic drug. Diabetes (DM) was defined as at least
two outpatient diagnoses of DM in the CAP or one hos-
pital discharge diagnosis of DM in CAP or one diagnosis
of DM plus an insulin or oral antidiabetic dispensing.
Patients with rheumatoid arthritis and diabetes were
identified as subgroups with chronic conditions because
these patients were likely to receive more lab tests at
regular intervals than the typical patient initiating a statin.
Patients with rheumatoid arthritis are of further interest
in that they may receive care primarily from a specialist
rather than an internist and therefore, may have different
patterns of laboratory use.
Patient characteristics and lab test results
Patient characteristics and potential confounders assessed
during the 6-month CAP included age (18–40; 41–64;
65+), sex, state of residence, insurance plan type (Health
Maintenance Organization, Medicare Advantage, Medi-
care Supplemental, Preferred Provider Organizations,
Indemnity, other), number of physician visits, number of
cardiologist visits, number of different drugs used, [11]
hospitalization in the 30 days prior to treatment initi-
ation, hospitalization for more than 30 days before treat-
ment initiation, number of days hospitalized, number of
outpatient lab test ordered, hypercholesterolemia, hyper-
tension, heart failure, myocardial infarction, coronary
revascularization, peripheral vascular disease, peripheral
Table 1 Definitions for high vs. low intensity lipid-lowering therapy
Generic entity of study medications Brand name High-intensity daily doses (mg) Low-intensity daily doses (mg)
Atorvastatin Lipitor > 10 ≤ 10
Fluvastatin Lescol All doses considered low-intensity
Lovastatin Mevacor > 40 ≤ 40
Pravastatin Pravachol All doses considered low-intensity
Rosuvastatin Crestor > 5 ≤ 5
Simvastatin Zocor > 40 ≤ 40
Ezetimibe Zetia
Ezetimibe + simvastatin fixed combination Vytorin If simvastatin component > 40 If simvastatin component ≤ 40
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larization, pre-diabetes, diabetes, arthritis, COPD, oxygen
canister use, and obesity. Clinical covariates were
assessed based on the presence of ICD-9 diagnosis codes
(see Additional file 1: Appendix Table S1) in administra-
tive claims during the CAP. In this exploratory analysis,
we included a wide range of clinical covariates frequently
measured in claims-based studies.
Within the 6 months covariate assessment period we
identified all recorded outpatient lab test results for
23 commonly-performed lab tests, including lipid tests,
HbA1c, and others (see Additional file 1: Appendix
Table S2). Additionally, we used CPT-4 codes to identify
all labs for which charges were claimed during the CAP.
We chose to include 23 lab tests to increase the prob-
ability that patients would have multiple lab tests per-
formed and that we would be able to asses whether lab
values were missing at the patient level or the test level.
In comparative effectiveness research, as in other areas
of clinical epidemiology, missing data are both common
and problematic. Imputation of missing values may
increase precision and validity of effect estimates. The
imputation literature recommends including not only pre-
exposure patient characteristics and treatment infor-
mation in the prediction of missing values but also
information on the outcome status [12]. In our example,
outcomes of interest were the incidence of myocardial
infarction (assessed with a positive predictive value of
94%); [13] hospitalization for acute coronary syndrome
(ACS) that included a coronary revascularization pro-
cedure; stroke; and death attributed to any cause (see
Additional file 1: Appendix Table S3). Follow-up time
started 1 month after initiation of a cholesterol-lowering
drug (Figure 2). Patients were censored at the time of
discontinuation of the index drug, any of the outcomes,
disenrollment, or study end (June 30, 2010), whichever
came first.
Analysis
In this analysis, ascertainment of performing a lab test
refers only to tests performed in the outpatient setting.We determined the proportion of patients who had at
least one such lab test performed out of the 23 study lab
tests and then focused on 3 specific cardiovascular risk
markers: LDL, HDL, and HbA1c [14]. In sensitivity ana-
lyses, we extended the 6-month covariate assessment
period to 9 and to 12 months in an effort to capture
more lab test results.
In order to quantify differential lab test performance
and result availability, we computed the number of lab
tests performed (as measured by the presence of CPT-4
codes) and the proportion of those with test results
available in the linked database. We then cross-tabulated
these data with patient and system characteristics.
For each of the LDL, HDL, and HbA1c cardiovascular
disease risk markers, any factors associated with a com-
pleted test were identified in a multivariate logistic re-
gression that predicted whether the outpatient lab test
was performed, as a function of the patient and system
characteristics described above plus statin/Vytorin expos-
ure and cardiovascular outcome status. We then deter-
mined overall sensitivity and specificity for the predicted
probabilities of test performance and model c-statistics.
In order to explore the performance of imputation
strategies, we fit linear regression models for the patients
who had lab test results available, in order to predict the
actual LDL, HDL, and HbA1c. In instances where patients
received multiple tests, we used the value from the last
test. We assumed normal distributions of test results as
reasonable approximations, although data were slightly
skewed. We express the proportion of explained variation
as the observed R2 from the linear regression models.
Lastly, we investigated the relationship between the
completion of a lab test, the availability of test results in
our database, and whether the test results themselves
differed between study exposure groups stratified by RA
and diabetes.
Results
Over the study period we identified 703,484 patients
who met the study eligibility criteria and initiated lipid-
lowering therapy with statins, ezetimibe, or a combination
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least one of the 23 study lab tests in the 6 months before
treatment (Table 2). This proportion increased to 72% if
the covariate assessment period was extended to 9 months
before treatment, and to 74% during a 12-month period.
For patients with diabetes or RA the proportions were
higher (80% during 6 months) but showed equally small
increases if the covariate assessment period was extended
(83% and 84%). For LDL and HbA1c tests, the proportion
of patients with a recorded charge for at least one test
during the 6 months before initiation of lipid-lowering
therapy was about 60% and 17%, respectively. For patients
with diagnosed diabetes, 68% had a charge for an HbA1c
test (Table 2).
Overall and regardless of having a test performed, the
proportion of patients with any outpatient lab test
results available in the linked database was about 30%,
which was similar in patients with diabetes or RA. Lab
test results for LDL or HDL were available for about
20% of patients during the 6 months before initiation of
lipid-lowering therapy.
Table 3 shows whether any of 23 outpatient lab tests, in-
cluding LDL, HDL and HbA1c were performed within the
6 months before initiating lipid-lowering therapy cross-
tabulated by a range of patient and health system charac-
teristics. Overall, 481,133 (68%) of study patients had
claims evidence of an outpatient lab test and 42% thereof
had results available in the study data (29% of all patients).
The proportion with at least one lab test performed varied
substantially by patient characteristics, while test result
availability varied little, and only for variables such as
system characteristics and state of residence (Table 3).
Having been hospitalized in the 30 days before the ini-
tiation of lipid-lowering treatment was negatively asso-
ciated with receiving an outpatient test, likely because
the relevant lab tests were performed during the hos-
pitalization and as such do not appear as outpatient lab
tests. Some patients hospitalized for acute coronary syn-
drome or MI may have received lipid-lowering therapy
for secondary prevention without the need for a lab test.
This is supported by the fact that patients with both re-
cent MI and ACS had a lower than average proportion
with at least one test performed (24% and 40% compared
with an average of 68%). A code for hypercholesterolemia
is frequently accompanied by an LDL test performed
(80%) likely because the test ordering is accompanied
with such a billing code.
Patients with Medicare Supplemental coverage (43,645)
had a much lower proportion of claims for LDL tests
performed (18%), and of those only 2% had results avail-
able. The lab test provider may not have included the
secondary payer on the claim.
The two lab test providers that provided data to the
insurer do not operate in some states; for example, theavailability of lab test results in one state was as low
as 2% for LDL. Such low recording would not be
dependent directly on patient characteristics as it affects
an entire state and is driven by factors other than health
status, though clinically relevant patient characteristics
have varying prevalences across states.
Some patients resided in states not primarily covered
by the health plan studied, and are covered only via
accounts for nationally operating businesses (e.g., if the
employer is based in another state, all employees may be
members of a health plan in that other state, rather than
the state of residence). For these patients, the availability
of LDL test results is less than 10%. One state (#12)
stands out as having a small proportion of patients with
an outpatient LDL test performed (24%), but a much
larger proportion of patients have a result available (51%).
In this state, a larger proportion of providers are under
HMO capitation agreements. Within these plans, under-
recording of tests performed may be the result of
bundled payment arrangements; however, results are still
forwarded by the lab test providers resulting in the para-
dox of having more lab test results available in our data-
base than performed as recorded in claims data. Among
patients with Diabetes or RA, we found fundamentally
similar results. Among elderly patients lab test results
were more likely to be available among Medicare advan-
tage enrollees than those patients covered through Medi-
care supplemental insurance (Table 4).
Based on patient and system characteristics plus ex-
posure and outcome status it was possible to predict
with high sensitivity (97%) and specificity (94%) whether
outpatient lab tests were performed in the 6 months
before treatment initiation. The corresponding model
c-statistics of the logistic regression models were between
0.89 and 0.93 (Figure 3), indicating a very high predictive
capacity. Strong independent associates of having an out-
patient LDL test performed were a diagnosis of hyper-
cholesterolemia or obesity, and carotid revascularization.
Associates of low probability of doing LDL lab tests were
recent hospitalization and being diagnosed with RA.
Being older than 65 also decreased the chance of an
LDL lab test, likely because of test underreporting due
to bundled payments. Initiating high-intensity lipid-
lowering treatment and dying in the study follow-up
period were correlates of not having an outpatient LDL,
HDL, or HBA1c test performed. Not surprisingly, the
strongest predictor of having an HBA1c test performed
was a diagnosis of diabetes or pre-diabetes.
Among the patients for whom LDL, HDL, or HBA1c
test levels were available, we then attempted to predict
the actual lab levels based on their recorded patient and
system characteristics. Using all observed factors
described above, 17% of the variation could be explained
(Figure 4). Young age was the strongest correlate of
Table 2 Number of patients with at least one lab test performed and claimed among 703,484 initiators of statins and/or ezetimibe using 6, 9, and 12-month
confounder assessment periods (CAPs)
All
patients
Number (%) of patients with at least 1 lab test
performed*
Number (%) of patients with at least 1 LDL lab test
performed
Number (%) of patients with at least 1 LDL lab test
performed
6 month CAP 9 month CAP 12 month CAP 6 month CAP 9 month CAP 12 month CAP 6 month CAP 9 month CAP 12 month CAP
N % N % N % N % N % N % N % N % N %
All patients 703,484 481,133 68% 505,161 72% 520,559 74% 421,708 60% 445,205 63% 460,293 65% 121,764 17% 132,358 19% 139,784 20%
DM patients 111,684 89,344 80% 92,185 83% 93,952 84% 74,576 67% 78,598 70% 81,104 73% 76,413 68% 79,932 72% 81,965 73%
RA patients 4,523 3,676 81% 3,774 83% 3,840 85% 2,650 59% 2,813 62% 2,915 64% 839 19% 918 20% 984 22%




























Patients with at least 1
of any 23 lab tests1)
Patients with at least
1 LDL test
Patients with at least
1 HDL test

















N % N % % of
performed
N % N % % of
performed
N % N % % of
performed
All patients 703,484 481,133 68 204,143 29 42 421,708 60 178,254 25 42 417,598 59 176,780 25 42 121,764 17 56,653 8 47
Age
18-40 71,396 52,674 74 23,861 33 45 48,565 68 21,313 30 44 48,021 67 21,150 30 44 12,424 17 5,770 8 46
41-64 489,581 363,406 74 150,096 31 41 329,097 67 131,999 27 40 325,945 67 130,912 27 40 92,076 19 40,635 8 44
65+ 142,507 65,053 46 30,186 21 46 44,046 31 24,942 18 57 43,632 31 24,718 17 57 17,264 12 10,248 7 59
Male sex 378,177 256,537 68 107,876 29 42 225,308 60 94,715 25 42 223,007 59 93,962 25 42 66,202 18 30,286 8 46
# of days hospitalized 1 1 1 0 54 0 51 93 0 55 0 51 91 1 91 1 78 86
Hospitalized in 30 days
before treatment
initiation (y/n)
52,959 29,933 57 8,871 17 30 15,942 30 5,738 11 36 15,929 30 5,691 11 36 6,353 12 2,483 5 39
Hospitalized in
31 to 180 days
before treatment
initiation (y/n)
39,304 28,823 73 10,569 27 37 18,889 48 7,546 19 40 18,790 48 7,491 19 40 7,852 20 3,405 9 43
Any coronary
hospitalization**
43,507 25,909 60 7,468 17 29 13,821 32 4,911 11 36 13,775 32 4,869 11 35 5,545 13 2,100 5 38
# of cardiologist visits 0 0 0 0 0 0 0 0 0
# of other
physician visits
3 4 3 3 3 3 3 4 3
Number of
different drugs
4 4 4 4 4 4 4 6 5
# of lab tests
performed
6 9 7 9 6 9 6 12 8
Vascular conditions:
Hypercholesterolemia 358,649 308,261 86 100,890 28 33 286,144 80 88,027 25 31 282,875 79 87,016 24 31 74,655 21 23,200 6 31
Hypertension 351,542 244,573 70 100,813 29 41 207,406 59 85,722 24 41 205,531 58 84,903 24 41 75,677 22 33,388 9 44
Heart failure 16,008 10,057 63 3,243 20 32 5,082 32 1,917 12 38 5,064 32 1,891 12 37 2,884 18 1,089 7 38
Acute MI 20,797 11,127 54 2,673 13 24 5,074 24 1,709 8 34 5,046 24 1,698 8 34 1,966 9 714 3 36
Old MI 5,166 3,734 72 998 19 27 2,345 45 714 14 30 2,320 45 705 14 30 873 17 293 6 34
Acute coron. syndrome 63,781 40,721 64 12,776 20 31 25,407 40 9,242 14 36 25,206 40 9,155 14 36 9,328 15 3,791 6 41
TIA/stroke 16,747 9,764 58 3,086 18 32 5,731 34 2,098 13 37 5,692 34 2,080 12 37 2,255 13 845 5 37





















Table 3 Patients with lab test results reported in study population of 703,484 initiators of statins or ezetimibe using a 6-month covariate assessment period*
(Continued)
PVD 8,032 5,489 68 1,868 23 34 3,241 40 1,300 16 40 3,260 41 1,284 16 39 1,515 19 642 8 42
Coronary revasc2) 22,575 13,317 59 3,581 16 27 7,098 31 2,377 11 33 7,069 31 2,351 10 33 2,610 12 942 4 36
Peripheral revas 987 748 76 261 26 35 388 39 171 17 44 394 40 170 17 43 204 21 90 9 44
Diabetes 111,684 89,344 80 34,137 31 38 74,576 67 28,032 25 38 73,937 66 27,693 25 37 76,413 68 26,959 24 35
Pre-diabetes 9,916 8,941 90 2,559 26 29 7,957 80 2,032 20 26 7,877 79 2,016 20 26 6,258 63 1,569 16 25
Rheumatoid arthritis 4,523 3,676 81 1,520 34 41 2,650 59 935 21 35 2,620 58 926 20 35 839 19 315 7 38
Recorded obesity 20,533 17,354 85 5,295 26 31 15,138 74 4,307 21 28 14,971 73 4,251 21 28 6,897 34 1,956 10 28
COPD 27,318 18,918 69 6,382 23 34 13,236 48 4,855 18 37 13,144 48 4,818 18 37 4,557 17 1,708 6 37
Use of oxygen tank 105 59 56 20 19 34 41 39 13 12 32 42 40 13 12 31 20 19 8 8 40
Plan type: Indemnity 3,942 3,391 86 807 20 24 3,149 80 696 18 22 3,132 79 698 18 22 823 21 181 5 22
HMO 202,910 109,821 54 100,426 49 91 95,306 47 92,427 46 97 94,360 47 91,683 45 97 28,471 14 30,241 15 106
Medicare Advantage 62,459 37,744 60 24,757 40 66 28,014 45 20,468 33 73 27,758 44 20,304 33 73 11,658 19 8,622 14 74
Medicare Supplemental 43,645 15,519 36 1,294 3 8 7,822 18 1,000 2 13 7,745 18 994 2 13 2,647 6 285 1 11
Other 22,274 10,323 46 4,057 18 39 8,677 39 3,486 16 40 8,593 39 3,456 16 40 2,422 11 1,153 5 48
Preferred Provider Org. 368,254 304,335 83 72,802 20 24 278,740 76 60,177 16 22 276,010 75 59,645 16 22 75,743 21 16,171 4 21
State of residence: 1 194,150 97,286 50 51,523 27 53 83,875 43 46,332 24 55 82,694 43 46,342 24 56 25,050 13 16,146 8 64
2 23,642 20,159 85 9,281 39 46 18,674 79 8,517 36 46 18,678 79 8,521 36 46 5,416 23 2,352 10 43
3† 5,006 3,783 76 359 7 9 3,420 68 318 6 9 3,395 68 311 6 9 923 18 85 2 9
4 64,242 53,997 84 30,197 47 56 49,458 77 27,231 42 55 48,892 76 26,855 42 55 13,198 21 7,569 12 57
5 36,365 29,200 80 4,805 13 16 25,522 70 3,635 10 14 25,903 71 3,604 10 14 6,872 19 917 3 13
6 48,045 37,348 78 8,630 18 23 32,056 67 6,583 14 21 31,752 66 6,476 13 20 8,929 19 1,723 4 19
7 13,847 11,833 85 359 3 3 10,773 78 260 2 2 10,647 77 259 2 2 2,678 19 44 0 2
8 28,450 23,108 81 6,178 22 27 20,781 73 5,309 19 26 20,627 73 5,276 19 26 5,877 21 1,461 5 25
9 8,703 7,401 85 1,089 13 15 6,789 78 875 10 13 6,772 78 886 10 13 1,812 21 243 3 13
10† 3,753 2,464 66 1,183 32 48 2,226 59 1,097 29 49 2,188 58 1,083 29 49 710 19 369 10 52
11 4,864 3,610 74 2,310 47 64 3,217 66 2,030 42 63 3,137 64 2,029 42 65 1,015 21 648 13 64
12 64,237 24,644 38 36,009 56 146 15,190 24 32,988 51 217 14,979 23 32,722 51 218 6,068 9 12,646 20 208
13 85,926 71,455 83 22,481 26 31 63,065 73 18,108 21 29 62,703 73 17,993 21 29 19,587 23 5,464 6 28
Other 44,110 35,064 79 5,628 13 16 31,850 72 4,867 11 15 31,462 71 4,839 11 15 8,949 20 1,446 3 16
14† 3,804 3,311 87 116 3 4 3,113 82 100 3 3 3,107 82 99 3 3 876 23 31 1 4
15 74,340 56,470 76 23,995 32 42 51,699 70 20,004 27 39 50,662 68 19,485 26 38 13,804 19 5,509 7 40
* Study period starts July 1, 2005, ensuring a minimum CAP of 6 months with lab test results coverage and a pre-CAP of 6 months.
** Hospitalization with primary discharge code for acute MI, ACS, PCTA, PCI, CABG.
† States with no WellPoint presence.
1) This is limited to 23 lab test results reported in our study database.
2) PCTA, PCI, CABG.





















Table 4 Cross-tabulation between states and Medicare Advantage and Medicare Supplement status
Patients with at least 1 of any 23 lab tests1)
Patients in HMO or PPO Patients in Medicare Advantage Patients in Medicare Supplemental



















1 87,110 52 48,838 29 56 3,999 51 1,978 25 49 5,881 31 625 3 11
2 17,068 89 8,331 43 49 174 85 95 46 55 574 37 92 6 16
3† 3,507 81 329 8 9 16 44 12 33 75 141 39 3 1 2
4 53,350 86 30,037 48 56 112 84 64 48 57 519 26 92 5 18
5 26,240 84 4,454 14 17 1,036 80 167 13 16 999 38 55 2 6
6 30,291 86 7,265 21 24 2,850 79 1,139 32 40 4,012 45 185 2 5
7 11,050 89 346 3 3 0 0 1 100 0 564 47 6 1 1
8 22,277 85 6,068 23 27 4 14 7 24 175 692 34 71 3 10
9 6,449 89 1,003 14 16 0 0 0 0 0 278 40 8 1 3
10† 2,372 66 1,144 32 48 3 23 5 38 167 5 31 0 0 0
11 3,547 76 2,289 49 65 1 33 2 67 200 38 21 9 5 24
12 15,645 43 19,387 54 124 6,560 30 14,189 65 216 105 39 15 6 14
13 46,115 86 15,049 28 33 22,884 84 7,035 26 31 1,543 39 126 3 8
Other 32,651 81 5,515 14 17 54 39 54 39 100 153 37 5 1 3
14† 3,256 88 113 3 3 0 0 0 0 0 7 30 0 0 0
15 53,228 82 23,060 36 43 51 59 9 10 18 8 33 2 8 25
† States with no WellPoint presence.
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levels, suggesting that in younger age initiation of lipid-
lowering therapy was more driven by lab test results, i.e.
primary prevention, while in older age past coronary
events and other risk factors were the triggers for statin
initiation despite lower LDL levels (−17 mg/dl).
Higher intensity of lipid lowering treatment generally
was correlated with a lower proportion of outpatient
LDL tests performed, a lower fraction of LDL test results
available in the database, and lower LDL serum levels
(Table 5). For example, among high dose simvastatin
initiators (>40 mg/day), 52% had an outpatient LDL test
performed before treatment start (63% for lower dose
simvastatin). Of those patients, 37% had a test result
available (42%), and the mean LDL serum level was
135.6 mg/dl compared to 147.3 mg/dl for patients started
on low-intensity simvastatin. Mean LDL levels were
generally lower in patients with diabetes who initiated
lipid-lowering therapy.Discussion
We studied the characteristics of laboratory test informa-
tion in a pharmacoepidemiologic research data source
that enriches longitudinal claims data with outpatient lab
test results data, which makes it possible to better adjustfor biomarkers of cardiac risk in comparative effective-
ness studies. In an example cohort study of 703,484
patients initiating various lipid-lowering therapies, 68%
of patients had at least one of a set of 23 study lab tests
performed in the 6 months before treatment, and 42% of
those had test results available. LDL test results were
available for 24% of statin initiators, a non-trivial level
of missingness that needed to be addressed in order to
preserve the validity and generalizability of findings.
Missingness due to absence of lab tests being performed
followed a complex pattern that is largely explained by
hospitalization, clinical practice guidelines which differ
for primary and secondary prevention of coronary heart
disease, and by some health care system characteristics.
Several key points regarding these patterns arose and
have implications for conducting comparative effective-
ness research studies in such enriched data sources.
Operational aspects
A covariate assessment period of 6 months was suffi-
cient to capture the majority of outpatient lab tests per-
formed. Extending the period to 9 and 12 months, and
thus extending the required pre-exposure enrollment
period, provided few additional observed lab tests but
may disproportionally reduce the cohort size if working
with health plans that have high enrollee turnover rates.
Figure 3 Associates of selected outpatient lab tests performed in patients initiating lipid-lowering treatment according to claims data
in 703,484 patients from a logistic regression model (darker means stronger association).
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Figure 4 Correlates of selected lab test results among patients with lab test results available (darker means stronger correlations).
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Table 5 LDL tests performed and LDL test results available by lipid lowering treatment in patients initiating
lipid-lowering therapy, including patient subgroups with diabetes (DM) or rheumatoid arthritis (RA)
All patients LDL test performed LDL test results available LDL level HDL level




mean s.d. mean s.d.
All Any statin alone 655,211 93 395,496 60.4 165,380 25.2 41.8 145.3 38.6 50.2 14.5
Any statin high intensity* 173,979 25 98,309 56.5 41,320 23.7 42.0 144.2 45.5 49.2 14.3
Any statin low intensity 481,232 68 297,187 61.8 124,060 25.8 41.7 145.7 36 50.6 14.6
Simvastatin alone 282,658 40 176,697 62.5 73,193 25.9 41.4 147.0 36.3 50.2 14.4
Simvastatin high dose
(>40 mg)
11,354 2 5,912 52.1 2,192 19.3 37.1 135.6 49.5 48 13.6
Simvastatin low dose 271,304 39 170,785 62.9 71,001 26.2 41.6 147.3 35.8 50.2 14.4
Vytorin alone 24,931 4 12,966 52 6,820 27.4 52.6 142.2 47.6 49.6 14.3
Vytorin high dose
(>40 mg simvast)
1,069 0 563 52.7 223 20.9 39.6 124.1 56.7 48.1 13.5
Vytorin low dose 23,862 3 12,403 52 6,597 27.6 53.2 142.8 47.1 49.6 14.4
Ezetimibe alone 20,509 3 11,412 55.6 5,334 26 46.7 143.2 38.1 51.5 14.9
Ezetimibe + statin 2,833 0 1,834 64.7 720 25.4 39.3 145.7 47.7 48.2 13.5
Total: 703,484
DM Any statin alone 103,664 93 69,788 67.3 25,927 25 37.2 124.8 37.4 46.5 13.1
Any statin high intensity* 28,472 26 18,069 63.5 6,909 24.3 38.2 122.3 43.3 45.8 13.1
Any statin low intensity 75,192 67 51,719 68.8 19,018 25.3 36.8 125.7 35.0 46.8 13.1
Simvastatin alone 46,414 42 32,207 69.4 11,670 25.1 36.2 126.8 35.6 46.5 13.0
Simvastatin high dose
(>40 mg)
2,498 2 1,513 60.6 521 20.9 34.4 117.1 46.2 45.6 12.6
Simvastatin low dose 43,916 39 30,694 69.9 11,149 25.4 36.3 127.2 35.0 46.6 13.0
Vytorin alone 4,049 4 2,324 57.4 1,086 26.8 46.7 122.9 44.4 45.6 13.4
Vytorin high dose
(>40 mg simvast)
269 0 169 62.8 58 21.6 34.3 105.6 41.6 46.3 14.0
Vytorin low dose 3,780 3 2,155 57 1,028 27.2 47.7 123.8 44.4 45.6 13.4
Ezetimibe alone 3,459 3 2,092 60.5 884 25.6 42.3 126.9 37.7 47.0 13.1
Ezetimibe + statin 512 1 372 72.7 135 26.4 36.3 133.1 44.5 44.8 11.8
Total: 111,684
RA Any statin alone 4,118 91 2,425 58.9 833 20.2 34.4 138.5 39.4 54.7 16.5
Any statin high intensity* 1,044 23 575 55.1 205 19.6 35.7 135.4 50.9 53.6 17.8
Any statin low intensity 3,074 68 1,850 60.2 628 20.4 33.9 139.5 34.8 55.1 16.0
Simvastatin alone 1,749 39 1,070 61.2 360 20.6 33.6 141.6 33.4 54.3 15.5
Simvastatin high dose
(>40 mg)
70 2 37 52.9 14 20 37.8 134.6 44.2 46.5 12.0
Simvastatin low dose 1,679 37 1,033 61.5 346 20.6 33.5 141.9 32.9 54.6 15.6
Vytorin alone 174 4 85 48.9 43 24.7 50.6 142.6 45.6 52.8 16.3
Vytorin high dose
(>40 mg simvast)
9 0 4 44.4 2 22.2 50.0 177.0 76.4 52 22.6
Vytorin low dose 165 4 81 49.1 41 24.8 50.6 141.0 44.5 52.8 16.3
Ezetimibe alone 210 5 126 60 55 26.2 43.7 137.5 31.3 56.8 16.7
Ezetimibe + statin 21 1 14 66.7 4 19 28.6 144.0 45.5 49.0 10.4
Total: 4,523
* See methods section for definition.
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betes have more outpatient lab tests available if their
healthcare providers monitor them more closely. Recenthospitalizations strongly decreased the number of out-
patient lab tests. It is likely that tests were performed
during the hospitalization, and if the test results were
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ing testing may not have been required for some time
after discharge.Selectiveness of lab tests performed
Patients with risk factors for cardiovascular events were
less likely to have lab tests performed. Many patients
with these characteristics receive lipid-lowering treat-
ment as secondary prevention, which is initiated inde-
pendent of serum lipid-levels more frequently than is
primary prevention. Indeed, treatment guidelines in
place since the late 1990s recommend that patients with
a major cardiac event should be treated with lipid lower-
ing medications [15,16]. In a prior study, patients who
initiated high-intensity lipid-lowering treatment were
less likely to have had an outpatient lab test performed
[17]. Because the presence of preexisting cardiac risk
factors is both a strong predictor of future events and a
predictor of missing data on lipid levels, disregarding the
missing information can be expected to bias findings of
non-randomized comparative effectiveness research in
this setting.Selectiveness of lipid lab test results available
Among patients who had lab test result available, those
who were subsequently initiated on higher-intensity
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cific example the combination of primary and secondary
prevention with lipid-lowering medications seems to
complicate the prediction of missing values, but in the
end is likely a reason why we could differentiate so well
between patients who have an outpatient LDL test per-
formed versus not (Figure 5). Once the outpatient lab
test results were available, we had moderate ability to
predict the exact lipid/HbA1c serum level. The resulting
mismeasurement of imputed lab test results suggests
that imputation of test results would provide only lim-
ited additional confounding control. However, estima-
tion precision would be increased because the analyzable
population would more than triple in our example
study.
It is likely that the specific patterns of missingness
of outpatient lab test results will vary depending on
the clinical scenario, health care practice, and system
constraints. It is encouraging that despite the non-
random missingness we were able to predict quite well
who would and would not receive a lab test result, which
is a good starting point for addressing this issue. How-
ever, our difficulty in predicting actual lab values is a
challenge to incorporating lab data through imputation
or weighting approaches in comparative effectiveness
research studies.
Conclusion
In a claims database linked with outpatient lab test
results, we found that lab tests are performed selectively
depending on patient risk factors and corresponding to
current treatment guidelines. Poor ability to predict lab
values and the high proportion of missingness reduces
the added value of lab tests for effectiveness research in
this setting.
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